Alan Bryce, MD, highlights key phase 3 advances in prostate cancer

In this video, Alan H. Bryce, MD, highlights what he believes are the most practice-changing advances in prostate cancer presented at the 2026 American Society of Clinical Oncology Annual Meeting, pointing to pivotal phase 3 data that could reshape treatment strategies for both localized and metastatic hormone-sensitive disease. Bryce is a professor of medical oncology at City of Hope Cancer Center in Phoenix, Arizona.

Bryce identified the phase 3 PROTEUS trial (NCT03767244) evaluating perioperative apalutamide (Erleada) plus androgen deprivation therapy (ADT) in patients with high-risk localized prostate cancer as the standout presentation from this year's meeting. Results presented at the conference showed that the regimen significantly improved metastasis-free survival, pathological complete response or minimal residual disease, event-free survival, and time to first subsequent therapy compared with ADT alone.¹ He also noted that 81.6% of patients in the apalutamide arm and 83.0% in the placebo arm achieved testosterone recovery to 200 ng/dL or greater.

Bryce also discussed the phase 3 TALAPRO-3 trial (NCT04821622), which evaluated talazoparib (Talzenna) in combination with enzalutamide (Xtandi) in patients with homologous recombination repair (HRR)-mutated metastatic hormone-sensitive prostate cancer. He said the study demonstrated a clear improvement in radiographic progression-free survival, with the greatest benefit observed among patients with BRCA2 mutations, while also noting encouraging signals in other HRR-altered populations, including ATM, BRCA1, and CDK12.² Bryce remarked that the findings align with the growing body of evidence supporting PARP inhibitors in biomarker-selected prostate cancer populations.

According to Bryce, these findings position the combination as a likely future treatment option for appropriately selected patients. The FDA recently granted priority review to a supplemental new drug application for the regimen, issuing a PDUFA target action date in the fourth quarter of 2026.

.

REFERENCES